Log in

NASDAQ:BMRN - BioMarin Pharmaceutical Stock Price, Forecast & News

$79.92
-0.16 (-0.20 %)
(As of 12/8/2019 09:19 AM ET)
Today's Range
$79.62
Now: $79.92
$80.99
50-Day Range
$68.30
MA: $75.19
$81.28
52-Week Range
$62.88
Now: $79.92
$100.13
Volume1.08 million shs
Average Volume1.54 million shs
Market Capitalization$14.36 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.31
BioMarin Pharmaceutical Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:BMRN
CUSIP09061G10
Phone415-506-6700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.49 billion
Cash Flow$0.21 per share
Book Value$16.67 per share

Profitability

Net Income$-77,210,000.00

Miscellaneous

Employees2,849
Market Cap$14.36 billion
Next Earnings Date2/20/2020 (Estimated)
OptionableOptionable

Receive BMRN News and Ratings via Email

Sign-up to receive the latest news and ratings for BMRN and its competitors with MarketBeat's FREE daily newsletter.


BioMarin Pharmaceutical (NASDAQ:BMRN) Frequently Asked Questions

What is BioMarin Pharmaceutical's stock symbol?

BioMarin Pharmaceutical trades on the NASDAQ under the ticker symbol "BMRN."

How were BioMarin Pharmaceutical's earnings last quarter?

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) issued its earnings results on Wednesday, October, 23rd. The biotechnology company reported $0.31 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.06 by $0.25. The biotechnology company earned $461.10 million during the quarter, compared to analyst estimates of $455.78 million. BioMarin Pharmaceutical had a negative net margin of 2.65% and a negative return on equity of 1.35%. BioMarin Pharmaceutical's revenue for the quarter was up 17.7% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.07) earnings per share. View BioMarin Pharmaceutical's Earnings History.

When is BioMarin Pharmaceutical's next earnings date?

BioMarin Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for BioMarin Pharmaceutical.

What guidance has BioMarin Pharmaceutical issued on next quarter's earnings?

BioMarin Pharmaceutical issued an update on its FY 2019 earnings guidance on Wednesday, October, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $1.69-1.72 billion, compared to the consensus revenue estimate of $1.7 billion.

What price target have analysts set for BMRN?

17 brokers have issued 1 year price targets for BioMarin Pharmaceutical's shares. Their forecasts range from $77.00 to $157.00. On average, they anticipate BioMarin Pharmaceutical's stock price to reach $109.71 in the next year. This suggests a possible upside of 37.3% from the stock's current price. View Analyst Price Targets for BioMarin Pharmaceutical.

What is the consensus analysts' recommendation for BioMarin Pharmaceutical?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioMarin Pharmaceutical in the last year. There are currently 2 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioMarin Pharmaceutical.

What are Wall Street analysts saying about BioMarin Pharmaceutical stock?

Here are some recent quotes from research analysts about BioMarin Pharmaceutical stock:
  • 1. According to Zacks Investment Research, "BioMarin beat estimates for earnings and sales in Q3. Sales of BioMarin’s key orphan disease drugs – Vimizim and Kuvan – are being driven by strong demand trends. Its newest product, Palynziq is witnessing strong commercial uptake in the United States. BioMarin’s rare disease pipeline is progressing well. The company targets regulatory filings for Valrox by year-end and vosoritide in 2020. Growing pipeline focus on gene therapy agents is encouraging. Valrox, a gene therapy for hemophilia A, is anticipated to be transformational, if approved. However, any development setbacks related to its pipeline candidates can hurt the stock. Moreover, uneven quarterly product sales of Naglazyme and Vimzin, owing to infrequent ordering patterns in some ex-U.S. countries, are a concern. The stock has underperformed the industry this year. " (11/6/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our OW and $131 PT. We continue to see highly favorable risk/reward ahead of key pipeline updates over the next 12 months. BioMarin reported an in-line quarter, although the overwhelming focus of the call was on valrox (hemophilia A gene therapy). The valrox 3-year update is on track for a top-line by early June (ISTH late-breaker submission due June 7). Not much new color on valrox from the call: management continues to sound confident in durability and potential for accelerated pathway (BMRN’s filing decision by YE19). For investors, we think valrox is more of a show-me story, which is why the update in June is important, although at this point somewhat of an overhang, in our view." (4/26/2019)

Has BioMarin Pharmaceutical been receiving favorable news coverage?

News articles about BMRN stock have trended very negative this week, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. BioMarin Pharmaceutical earned a daily sentiment score of -3.7 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for BioMarin Pharmaceutical.

Who are some of BioMarin Pharmaceutical's key competitors?

What other stocks do shareholders of BioMarin Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioMarin Pharmaceutical investors own include Puma Biotechnology (PBYI), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Celgene (CELG), Array Biopharma (Arry) and Freeport-McMoRan (FCX).

Who are BioMarin Pharmaceutical's key executives?

BioMarin Pharmaceutical's management team includes the folowing people:
  • Mr. Jean-Jacques Bienaimé M.B.A., MBA, Chairman & CEO (Age 66)
  • Mr. Daniel K. Spiegelman, Exec. VP & CFO (Age 60)
  • Dr. Robert A. Baffi, Exec. VP of Technical Operations (Age 64)
  • Mr. Jeffrey Robert Ajer, Exec. VP & Chief Commercial Officer (Age 57)
  • Dr. Henry J. Fuchs, Pres of Worldwide R&D (Age 61)

Who are BioMarin Pharmaceutical's major shareholders?

BioMarin Pharmaceutical's stock is owned by many different of retail and institutional investors. Top institutional shareholders include First Trust Advisors LP (0.48%), Voya Investment Management LLC (0.44%), York Capital Management Global Advisors LLC (0.42%), Manning & Napier Group LLC (0.41%), Sumitomo Mitsui Trust Holdings Inc. (0.37%) and Pictet Asset Management Ltd. (0.33%). Company insiders that own BioMarin Pharmaceutical stock include Alan Lewis, Brian Mueller, Daniel K Spiegelman, Elaine J Heron, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer, Richard A Meier, Robert Baffi and V Bryan Lawlis. View Institutional Ownership Trends for BioMarin Pharmaceutical.

Which major investors are selling BioMarin Pharmaceutical stock?

BMRN stock was sold by a variety of institutional investors in the last quarter, including Pictet Asset Management Ltd., First Trust Advisors LP, York Capital Management Global Advisors LLC, Massachusetts Financial Services Co. MA, Point72 Asset Management L.P., Squarepoint Ops LLC, Parametric Portfolio Associates LLC and Voya Investment Management LLC. Company insiders that have sold BioMarin Pharmaceutical company stock in the last year include Brian Mueller, Daniel K Spiegelman, George Eric Davis, Henry J Fuchs, Jean Jacques Bienaime, Jeffrey Robert Ajer and V Bryan Lawlis. View Insider Buying and Selling for BioMarin Pharmaceutical.

Which major investors are buying BioMarin Pharmaceutical stock?

BMRN stock was bought by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, California Public Employees Retirement System, Public Employees Retirement Association of Colorado, CMH Wealth Management LLC, Comgest Global Investors S.A.S., National Pension Service, Brinker Capital Inc. and Fjarde AP Fonden Fourth Swedish National Pension Fund. View Insider Buying and Selling for BioMarin Pharmaceutical.

How do I buy shares of BioMarin Pharmaceutical?

Shares of BMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is BioMarin Pharmaceutical's stock price today?

One share of BMRN stock can currently be purchased for approximately $79.92.

How big of a company is BioMarin Pharmaceutical?

BioMarin Pharmaceutical has a market capitalization of $14.36 billion and generates $1.49 billion in revenue each year. The biotechnology company earns $-77,210,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis. BioMarin Pharmaceutical employs 2,849 workers across the globe.View Additional Information About BioMarin Pharmaceutical.

What is BioMarin Pharmaceutical's official website?

The official website for BioMarin Pharmaceutical is http://www.bmrn.com/.

How can I contact BioMarin Pharmaceutical?

BioMarin Pharmaceutical's mailing address is 770 Lindaro Street, San Rafael CA, 94901. The biotechnology company can be reached via phone at 415-506-6700 or via email at [email protected]


MarketBeat Community Rating for BioMarin Pharmaceutical (NASDAQ BMRN)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  1,303 (Vote Outperform)
Underperform Votes:  746 (Vote Underperform)
Total Votes:  2,049
MarketBeat's community ratings are surveys of what our community members think about BioMarin Pharmaceutical and other stocks. Vote "Outperform" if you believe BMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BMRN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/8/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel